biodexapharma.com (BDRX) - Long-Term Debt to Capital Coefficient
Biodexa Pharmaceuticals (BDRX) utilizes a method of reprocessing existing medications into microspheres, which reduces development costs and expands its patent portfolio. Research stability is maintained through partnerships with various contract laboratories. The market dynamics of the asset with the 0.00 indicator are presented below. The business relies on proprietary methods for the precise transport of drugs into neoplasms, ensuring financial stability within the oncology sector.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_BDRX_-_Biodexa-Pharmaceuticals_-_Long-Term-Debt-to-Capital "BDRX: Biodexa Pharma Long-Term Debt to Capital 04/28/2023 - 10/31/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Biodexa (BDRX)
Conservative asset selection requires the minimization of debt risks. This indicator measures the share of borrowed obligations with a maturity of more than one year relative to equity, determining the level of financial leverage. For Biodexa Pharmaceuticals (BDRX), with its liquidity deficit and risky trials, this balance is critical. By analyzing the ratio of long-term credit funds to equity on GURU.Markets, an investor can assess the company's dependence on external financing.